These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 7692189)
1. The efficacy of granulocyte colony-stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow. Schriber JR; Negrin RS; Chao NJ; Long GD; Horning SJ; Blume KG Leukemia; 1993 Oct; 7(10):1491-5. PubMed ID: 7692189 [TBL] [Abstract][Full Text] [Related]
2. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation. Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941 [TBL] [Abstract][Full Text] [Related]
3. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells. van Besien K; Margolin K; Champlin R; Forman S Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395 [TBL] [Abstract][Full Text] [Related]
4. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment. Bolwell BJ; Fishleder A; Andresen SW; Lichtin AE; Koo A; Yanssens T; Burwell R; Baucco P; Green R Bone Marrow Transplant; 1993 Dec; 12(6):609-14. PubMed ID: 7511016 [TBL] [Abstract][Full Text] [Related]
5. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies. Vose JM; Bierman PJ; Ruby E; Reed EC; Bishop MR; Tarantolo S; Kessinger A; Armitage JO Bone Marrow Transplant; 1996 Jun; 17(6):951-6. PubMed ID: 8807099 [TBL] [Abstract][Full Text] [Related]
6. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF. Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784 [TBL] [Abstract][Full Text] [Related]
7. Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial. Gorin NC; Coiffier B; Hayat M; Fouillard L; Kuentz M; Flesch M; Colombat P; Boivin P; Slavin S; Philip T Blood; 1992 Sep; 80(5):1149-57. PubMed ID: 1515637 [TBL] [Abstract][Full Text] [Related]
8. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant. Bolwell BJ; Goormastic M; Yanssens T; Dannley R; Baucco P; Fishleder A Bone Marrow Transplant; 1994 Dec; 14(6):913-8. PubMed ID: 7536072 [TBL] [Abstract][Full Text] [Related]
9. Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer. Kennedy MJ; Davis J; Passos-Coelho J; Noga SJ; Huelskamp AM; Ohly K; Davidson NE Cancer Res; 1993 Nov; 53(22):5424-8. PubMed ID: 7693341 [TBL] [Abstract][Full Text] [Related]
10. Granulocyte-colony-stimulating factor after allogeneic and autologous bone marrow transplantation in children. Saarinen UM; Hovi L; Juvonen E; Riikonen P; Möttönen M; Mäkipernaa A Med Pediatr Oncol; 1996 Jun; 26(6):380-6. PubMed ID: 8614373 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation. Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338 [TBL] [Abstract][Full Text] [Related]
12. In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies. Albin N; Douay L; Fouillard L; Laporte JP; Isnard F; Lesage S; Ozsahin H; Bardinet D; Najman A; Gorin NC Bone Marrow Transplant; 1994 Aug; 14(2):253-9. PubMed ID: 7994241 [TBL] [Abstract][Full Text] [Related]
13. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in serum in bone marrow transplanted patients. Sallerfors B; Olofsson T; Lenhoff S Bone Marrow Transplant; 1991 Sep; 8(3):191-5. PubMed ID: 1720339 [TBL] [Abstract][Full Text] [Related]
14. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma. Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500 [TBL] [Abstract][Full Text] [Related]
15. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial. Vose JM; Pandite AN; Beveridge RA; Geller RB; Schuster MW; Anderson JE; LeMaistre CF; Ahmed T; Granena A; Keating A; Fernandez Ranada JM; Stiff PJ; Tabbara I; Longo W; Copelan EA; Nichols C; Smith A; Topolsky DL; Bierman PJ; Lebsack ME; Lange M; Garrison L J Clin Oncol; 1997 Apr; 15(4):1617-23. PubMed ID: 9193361 [TBL] [Abstract][Full Text] [Related]
16. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial. Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838 [TBL] [Abstract][Full Text] [Related]
17. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Schmitz N; Dreger P; Zander AR; Ehninger G; Wandt H; Fauser AA; Kolb HJ; Zumsprekel A; Martin A; Hecht T Bone Marrow Transplant; 1995 Feb; 15(2):261-6. PubMed ID: 7539668 [TBL] [Abstract][Full Text] [Related]
18. GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation. Brandwein JM; Nayar R; Baker MA; Sutton DM; Scott JG; Sutcliffe SB; Keating A Exp Hematol; 1991 Mar; 19(3):191-5. PubMed ID: 1995310 [TBL] [Abstract][Full Text] [Related]
19. 4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation of relapsed, responding non-Hodgkin's lymphoma with granulocyte colony stimulating factor support results in reliable hematopoietic recovery. Biggs D; Stadtmauer E; Mangan P; Edelstein M; Powlis W; Buzby G; Magee D; Sachs B; Silberstein L Prog Clin Biol Res; 1994; 389():9-15. PubMed ID: 7535466 [No Abstract] [Full Text] [Related]
20. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]